photoaging hyaluronic acid, photoaging
Conditions
Interventions
Participants will undergo three treatment sessions at 1 month intervals, with standardized injection techniques using sharp technique over the face
Experimental Device
Intradermal non crosslinked hyaluronic acid
Sponsors
Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
Eligibility
Sex/Gender
All
Age
30 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Participants aged 30 to 60 years, both male and female. 2. Participants diagnosed by a dermatologic surgeon with moderate or higher photoaging according to the Glogau classification. 3. Participants of Thai Asian ethnicity.
Exclusion criteria
Exclusion criteria: 1. Pregnant or breastfeeding participants. 2. Participants with underlying conditions such as platelet disorders, coagulopathy, anemia, liver disease, malignancy, or immunodeficiency. 3. Participants who smoke or consume excessive alcohol. 4. Participants with active dermatitis, wounds, or facial skin infection. 5. Participants with a history of allergy to local anesthetics. 6. Participants taking hormonal therapy, oral contraceptives, or regular NSAIDs. 7. Participants taking anticoagulants or antiplatelet medications (e.g., aspirin). 8. Participants who received facial lifting procedures or thread lifting within 6 months. 9. Participants who received dermal fillers within 6 months. 10. Participants who received platelet-rich plasma (PRP) injections within 6 months. 11. Participants who received botulinum toxin injections within 6 months. 12. Participants who underwent collagen-stimulating laser treatments (e.g., picosecond laser, Er:YAG, Fractora, eMatrix) within 6 months. 13. Participants with a history of keloid or hypertrophic scarring. 14. Participants with psychiatric disorders diagnosed by a psychiatrist. 15. Participants unwilling to allow clinical photography for evaluation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| skin pliability/firmness baseline, 1 month after 1st treatment, 1 month after 2nd treatment and 1, 3 and 6 months after 3rd treatment Cutometer,Skin elasticity baseline, 1 month after 1st treatment, 1 month after 2nd treatment and 1, 3 and 6 months after 3rd treatment Cutometer | — |
Secondary
| Measure | Time frame |
|---|---|
| Skin hydration baseline, 1 month after 1st treatment, 1 month after 2nd treatment and 1, 3 and 6 months after 3rd treatment Corneometer,Melanin index baseline, 1 month after 1st treatment, 1 month after 2nd treatment and 1, 3 and 6 months after 3rd treatment Mexamater,Erythema index baseline, 1 month after 1st treatment, 1 month after 2nd treatment and 1, 3 and 6 months after 3rd treatment Mexamater,Individual Typology Angle baseline, 1 month after 1st treatment, 1 month after 2nd treatment and 1, 3 and 6 months after 3rd treatment Colorimeter,sebum level baseline, 1 month after 1st treatment, 1 month after 2nd treatment and 1, 3 and 6 months after 3rd treatment sebumeter,Skin quality baseline, 1 month after 1st treatment, 1 month after 2nd treatment and 1, 3 and 6 months after 3rd treatment Antera3D,Patient improvement scale 1 month after 1st treatment, 1 month after 2nd treatment and 1, 3 and 6 months after 3rd treatment improvement scale,Physician improvement scale 1 month after 1st treatment, 1 month after 2nd treatment and 1, 3 and 6 months after 3rd treatment improvement scale,Safety 1 month after 1st treatment, 1 month after 2nd treatment and 1, 3 and 6 months after 3rd treatment Adverse events,Pain score 1st treatment, 2nd treatment and 3rd treatment Visual analog scale | — |
Countries
Thailand
Contacts
Public ContactRungsima Wanitphakdeedecha
Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University
Outcome results
None listed